<DOC>
	<DOCNO>NCT00254033</DOCNO>
	<brief_summary>Apathy , lack motivation , affect 80 % Alzheimer 's disease ( AD ) patient . These amotivational symptom increase patient reliance caregiver , increase caregiver burden distress , increase risk patient institutionalization . Only 50 % patient apathy respond current treatment cholinesterase inhibitor . The mechanism apathy AD unknown hamper rational treatment . Our propose pilot study provide initial data require develop amphetamine challenge paradigm probe brain reward system . These result use develop large study evaluate role brain reward system apathy AD link information pharmacologic treatment . AD complex neurobiological illness need understood several level optimize treatment . At neurochemical level , one identify neurotransmitter abnormality accompany clinical symptom . The neurochemical level analysis provide link pathology symptom , , avenue biological therapy . Next , one translate knowledge neurochemical abnormality practical treatment symptom AD . This pilot allow u develop study address goal . Furthermore , large study define emerge concept apathy syndrome broad implication apathy many neuropsychiatric disease .</brief_summary>
	<brief_title>Apathy Associated With Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Dextroamphetamine</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>age &gt; 55 year meet DSMIV criterion primary degenerative dementia meet NINCDSARDA criterion probable Alzheimer 's Disease least one year 's duration mild moderate cognitive impairment ( Global Deterioration Scale GDS &lt; 6 , MiniMental State Examination &gt; 10 stable dose cholinesterase inhibitor least 3 month apathetic group : Neuropsychiatric Inventory ( NPI ) Apathy subscale score &gt; =2 abnormal biochemical screening : blood cell count , vitamin B12 , thyroid function test , syphilis screening test significant medical illness medical/neurological condition diminish cognitive function evidence seizure disorder Hachinski ischemic score &gt; 3 indicate vascular dementia brain compute tomographic ( CT ) scan reveal focal lesion , inconsistent AD electrocardiographic , laboratory physical evidence significant cardiovascular disease presence premorbid current psychiatric diagnosis include : major depression , schizophrenia , psychotic symptom severity likely provoke violent dangerous behaviour ( i.e. , command hallucination harm people persecutory delusion provoke violent reaction ) current past psychoactive substance abuse dependence ( include alcohol , exclude nicotine ) contraindication receive dextroamphetamine methylphenidate administration depot neuroleptic injection within one treatment cycle first visit</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Apathy</keyword>
	<keyword>Brain Reward System</keyword>
	<keyword>Dopamine</keyword>
	<keyword>Dextroamphetamine Challenge</keyword>
	<keyword>Methylphenidate</keyword>
</DOC>